Mr. Jorge D. Abraldes
CEO
ABR Laboratory LLC
450 N Park Rd, Suite 303
Hollywood , FL 33021-6917
United StatesFEI 3020570829Issued Feb 10, 2025Center for Drug Evaluation and Research (CDER)
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3020570829.
Violations3
Issue DateFeb 10, 2025
Product TypeDrugs
StatusOpen
Letter Details
Firm
ABR Laboratory LLC
Location
Mr. Jorge D. Abraldes
CEO
ABR Laboratory LLC
450 N Park Rd, Suite 303
Hollywood , FL 33021-6917
United States
FEI Number
3020570829
Country
United States
Issue Date
February 10, 2025
Issuing Office
Center for Drug Evaluation and Research (CDER)
Product Type
Drugs
Status
Open
Summary
ABR Laboratory LLC, a contract testing laboratory in Hollywood, Florida, was cited for significant Current Good Manufacturing Practice (CGMP) violations in the testing of finished pharmaceutical products. The FDA found that the firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods as required by 21 CFR 211.165(e), specifically using growth media compositions that differed from United States Pharmacopeia (USP) standards without demonstrating equivalence or superiority for microbial contamination testing of over-the-counter drug products. These control and methodology failures rendered the drug products tested by the firm adulterated under the Federal Food, Drug, and Cosmetic Act. The inspection was conducted September 9-13, 2024, with the warning letter issued February 10, 2025.
ABR Laboratory LLC FDA Warning Letter, February 10, 2025